Plain-English translation of NCT06598839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing thymosin alpha 1 (Tα1), a medication designed to boost the immune system, in patients who have just had surgery to remove early-stage lung cancer. Researchers want to see whether this medication can help prevent cancer from coming back and support the body's natural defenses after surgery. Half of the patients will receive the medication for 3 months following their operation, while the other half will be observed without this specific treatment.
After surgery for lung cancer, there's a window of time when the immune system is recovering and cancer cells might try to return. This trial exists because doctors want to know if strengthening the immune system during this critical period can help patients stay cancer-free longer.
If you join this trial, you'll have surgery to remove the cancerous part of your lung and lymph nodes (this is standard care). After surgery, you'll either receive the immune-boosting medication as injections or infusions for 3 months, or you'll be in the observation group and monitored without this medication. Throughout the study, you'll have blood tests to check for circulating cancer cells and how well your immune system is working. The trial involves regular follow-up visits to track your recovery and health.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Sponsor
Yousheng Mao
Enrollment target
~40 participants
Started
June 2024
Primary completion
September 2025
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yousheng Mao
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital